Big Data: Moving From Artificial Trials To A Smarter Regulatory Process
This year the EU Big Data Task Force intends to deliver an EU-wide strategy on how big data can be used to support the development and evaluation of new medicines. The recent massive growth of data generated by various technologies, such as ‘omics, portable devices, the internet of things and even social media, gives this task force an urgency for pharma and regulators. Bruno Boulanger discusses the impact this will have on how the pharmaceutical industry gathers and delivers data in the future.
You may also be interested in...
Biogen’s “recipe-driven qualification” knowledge management program standardizes data collection and reporting in the laboratory, with efficiency gains of 66%.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.